|  |
| --- |
| **Supplemental Table**　HRCT findings of anti-ARS antibody-associated interstitial lung disease in patients between initial treatment response |
| Characteristics | All subjects | κ value (95% CI) | Initial treatment response | p value |
| Improved | Stable | Worsened |
| No. of patients | 75 |  | 48 | 21 | 6 |  |
| Predominant distribution (1: BVB, 2: Peripheral, 3: Random) | (64/3/8) | 0.494 (0.171-0.817) | (43/1/4) | (16/2/3) | (5/0/1) | 0.380 |
| Right upper lobe/left superior lobe |  |  |  |  |  |  |
|  GGO, N (%) | 57 (76.0) | 0.773 (0.583-0.962) | 40 (83.3) | 12 (57.1) | 5 (83.3) | 0.066 |
|  Consolidation, N (%) | 10 (13.3) | 0.879 (0.643-1.000) | 6 (12.5) | 2 (9.5) | 2 (33.3) | 0.336 |
|  Reticulation, N (%) | 47 (62.7) | 1.000 (1.000-1.000) | 34 (70.8) | 9 (42.9) | 4 (66.7) | 0.083 |
|  Traction bronchiectasis, N (%) | 11 (14.7) | 0.583 (0.295-0.870) | 9 (18.8) | 2 (9.5) | 0 (0.0) | 0.501 |
| Right middle lobe/lingula of left lung |  |  |  |  |  |  |
|  GGO, N (%) | 70 (93.3) | 0.361 (-0.120-0.862) | 46 (95.8) | 18 (85.7) | 6 (100.0) | 0.327 |
|  Consolidation, N (%) | 25 (33.3) | 0.952 (0.859-1.000) | 18 (37.5) | 5 (23.8) | 2 (33.3) | 0.547 |
|  Reticulation, N (%) | 67 (89.3) | 0.790 (0.560-1.000) | 44 (91.7) | 17 (81.0) | 6 (100.0) | 0.309 |
|  Traction bronchiectasis, N (%) | 44 (58.7) | 0.808 (0.647-0.968) | 27 (56.3) | 11 (52.4) | 6 (100.0) | 0.094 |
| Right and left lower lobe |  |  |  |  |  |  |
|  GGO, N (%) | 72 (96.0) | 0.649 (0.171-1.000) | 46 (95.8) | 20 (95.2) | 6 (100.0) | >0.999 |
|  Consolidation, N (%) | 52 (69.3) | 0.913 (0.794-1.000) | 37 (77.1) | 10 (47.6) | 5 (83.3) | **0.045\*** |
|  Reticulation, N (%) | 74 (98.7) | 0.658 (-0.006-1.000) | 48 (100.0) | 20 (95.2) | 6 (100.0) | 0.360 |
|  Traction bronchiectasis, N (%) | 74 (98.7) | 0.952 (0.859-1.000) | 47 (97.9) | 21 (100.0) | 6 (100.0) | >0.999 |
| Honeycomb, N (%) | 1 (1.3) | 1.000 (1.000-1.000) | 1 (2.1) | 0 (0.0) | 0 (0.0) | >0.999 |
| Lower volume loss, N (%) | 70 (93.3) | 0.658 (-0.006-1.000) | 47 (97.9) | 19 (90.5) | 4 (66.7) | **0.016\*** |
| Lower predominance, N (%) | 73 (97.3) | 1.000 (1.000-1.000) | 47 (97.9) | 21 (100.0) | 5 (83.3) | 0.230 |
| Emphysema, N (%) | 13 (17.3) | 0.892 (0.744-1.000) | 9 (18.8) | 3 (14.3) | 1 (16.7) | 0.893 |
| Cyst, N (%) | 13 (17.3) | 0.936 (0.811-1.000) | 7 (14.6) | 6 (28.6) | 0 (0.0) | 0.252 |
| Enlarged mediastinal lymph node, N (%) | 13 (17.3) | 0.866 (0.684-1.000) | 6 (12.5) | 5 (23.8) | 2 (33.3) | 0.188 |
| Pleural thickening or irregularity, N (%) | 13 (17.3) | 0.822 (0.626-1.000) | 10 (20.8) | 3 (14.3) | 0 (0.0) | 0.637 |
| HRCT: high-resolution computed tomography; BVB: bronchovascular bundle; GGO: ground-glass opacity. \*P value <0.05. |  |  |  |